Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel antibiotics to combat serious multidrug-resistant infections. Its primary product candidate, Xerava (eravacycline), is a synthetic fluorocycline designed for intravenous use as a first-line treatment for multidrug-resistant infections, particularly those caused by Gram-negative bacteria. The company has conducted Phase III clinical trials, including IGNITE1 and IGNITE4, to evaluate Xerava's safety and efficacy for treating complicated intra-abdominal infections. In addition to Xerava, Tetraphase is advancing other product candidates, such as TP-271, which targets respiratory diseases caused by antibiotic-resistant pathogens, and TP-6076, aimed at treating multidrug-resistant Gram-negative infections. The company holds a licensing agreement with Everest Medicines Limited to develop and commercialize Xerava in various Asian markets. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase Pharmaceuticals is a subsidiary of La Jolla Pharmaceutical Company.